Renovis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of neurological and inflammatory diseases in the United States. It focuses on identifying and developing treatments for pains, such as osteoarthritic pain or pain associated with osteoarthritis, and neuropathic pain or nerve pain. The company offers VR1 antagonist program that develops and maintains various pain states, including inflammatory and neuropathic pain; P2X3 and P2X2/3 receptors that are therapeutic targets for medical needs in the areas of chronic pain and bladder dysfunction; and P2X7, which represents molecular target for new therapies in the areas of rheumatoid arthritis and inflammatory bowel disease. Renovis has strategic alliances with Pfizer, Inc. to research, develop, and commercialize small molecule compounds that target VR1; and Genentech, Inc. to discover and develop drugs that inhibit pathological or tumor angiogenesis. The company was founded in 2000 and is based in South San Francisco, California.